About this episode
SQZ Biotech believes its platform technology can enable the engineering of virtually any function into any cell type allow for a new world of cell therapies to revolutionize the treatment of diseases. As its name implies, it does this by squeezing a cell to momentarily disrupt its membrane to allow it to insert a range of substances. We spoke to Armon Sharei, CEO of SQZ Biotech, about the company’s platform technology, its initial focus on oncology and auto-immune diseases, and the broad potential for this approach.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report
Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending
Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending
Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending
How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending